You just read:

I-Mab Receives IND Approval from the US FDA to Initiate Clinical Trials for Its Proprietary TJC4, a Potential Global Best-in-Class Anti-CD47 Monoclonal Antibody

News provided by

I-Mab Biopharma

Jan 28, 2019, 08:58 ET